Harvard Apparatus Regenerative Technology Inc.
HRGN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$57.82M
Close$
$0.72
68.6% downside
Current Fair Value
68.6% downsideOvervalued by 68.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $57.82 Million |
|---|---|
| Enterprise Value | $58.72 Million |
| Earnings per Share | $-0.42 |
| Beta | -0.18 |
| Outstanding Shares | 17,580,744 |
Return
| Return on Equity | 484.63% |
|---|---|
| Return on Assets | -396.62% |
| Return on Invested Capital | 491.89% |
Valuation & Multiples
| P/E Ratio | -5.79 |
|---|---|
| PEG | 82.41 |
| Price to Sales | - |
| Price to Book Ratio | -2.3 |
| Enterprise Value to Revenue | 68.36 |
| Enterprise Value to EBIT | -8.8 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | -0.91 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Harvard Apparatus Regenerative Technology Inc.
8 employees
CEO: Junli He
Harvard Apparatus Regenerative Technology Inc., a biotechnology firm currently conducting clinical trials, is dedicated to developing regenerative medical therapies. Its core mission involves addressing conditions affecting the gastroint...